These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 4838506)

  • 1. Physiological disposition of beta-phenylethylamine, 2,4,5-trimethoxyphenylethylamine, 2,3,4,5,6-pentamethoxyphenylethylamine and beta-hydroxymescaline in rat brain, liver and plasma.
    Cohen I; Fischer JF; Vogel WH
    Psychopharmacologia; 1974 Mar; 36(1):77-84. PubMed ID: 4838506
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of metabolism of mescaline and 3,4-dimethoxyphenylethylamine in humans.
    Charalampous KD
    Behav Neuropsychiatry; 1971; 2(11):26-9 passim. PubMed ID: 5566331
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of the stimulus properties of mescaline and 2,3,4-trimethoxyphenylethylamine.
    Winter JC
    J Pharmacol Exp Ther; 1973 Apr; 185(1):101-7. PubMed ID: 4693179
    [No Abstract]   [Full Text] [Related]  

  • 4. Structure-activity relationship studies on mescaline: the effect of dimethoxyphenylethylamine and N:N-dimethyl mescaline on the conditioned avoidance response in the rat.
    Smythies JR; Sykes EA
    Psychopharmacologia; 1966; 8(5):324-30. PubMed ID: 5923938
    [No Abstract]   [Full Text] [Related]  

  • 5. Oxidative metabolism of mescaline in the central nervous system. II. Oxidative deamination of mescaline and 2,3,4-trimethoxy-beta-phenylethylamine by different mouse brain area in vitro.
    Seiler N; Demisch L
    Biochem Pharmacol; 1971 Sep; 20(9):2485-93. PubMed ID: 5163157
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of chlorpromazine and haloperidol on the disposition of mescaline-14C in mice.
    Shah NS; Shah KR; Lawrence RS; Neely AE
    J Pharmacol Exp Ther; 1973 Aug; 186(2):297-304. PubMed ID: 4719782
    [No Abstract]   [Full Text] [Related]  

  • 7. Structure-activity relationship studies on mescaline. II. Tolerance and cross-tolerance between mescaline and its analogues in the rat.
    Smythies JR; Sykes EA; Lord CP
    Psychopharmacologia; 1966; 9(5):434-46. PubMed ID: 5998418
    [No Abstract]   [Full Text] [Related]  

  • 8. A comparative study of mescaline and 3,4-dimethoxy-phenylethylamine in isolated brain mitochondria and brain homogenate.
    Shah NS; Himwich HE
    Brain Res; 1971 Nov; 34(1):163-70. PubMed ID: 5124914
    [No Abstract]   [Full Text] [Related]  

  • 9. Psychoactivity of normacromerine in animals.
    Bourn WM; Keller WJ; Bonfiglio JF
    Life Sci; 1978 Sep; 23(11):1175-84. PubMed ID: 713693
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure-activity relationship studies on mescaline. 3. The influence of the methoxy groups.
    Smythies JR; Bradley RJ; Johnston VS; Benington F; Morin RD; Clark LC
    Psychopharmacologia; 1967; 10(5):379-87. PubMed ID: 5588333
    [No Abstract]   [Full Text] [Related]  

  • 11. Structure-activity-relationships of certain hallucinogenic substances based on brain levels.
    Vogel WH; Evans BD
    Life Sci; 1977 May; 20(10):1629-35. PubMed ID: 69244
    [No Abstract]   [Full Text] [Related]  

  • 12. Facilitation and disruption by mescaline and 3,4-dimethoxyphenylethylamine of shock avoidance in rats.
    Gorelick DA; Bridger WH
    Psychopharmacology (Berl); 1977 Apr; 52(2):157-63. PubMed ID: 407599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of psychotropic drugs and beta-diethylaminoethyl-diphenylpropylacetate (SKF 525-A) on mescaline-induced behavior and on tissue levels of mescaline in mice.
    Shah NS
    Biochem Pharmacol; 1976 Mar; 25(5):591-7. PubMed ID: 8055
    [No Abstract]   [Full Text] [Related]  

  • 14. Oxidative metabolism of mescaline in the central nervous system. IV. In vivo metabolism of mescaline and 2,3,4-trimethoxy-beta-phenylethylamine.
    Seiler N; Demisch L
    Biochem Pharmacol; 1974 Jan; 23(2):273-87. PubMed ID: 4813344
    [No Abstract]   [Full Text] [Related]  

  • 15. Mescaline: no tolerance to excitatory effects.
    Bridger WH; Mandel IJ; Stoff DM
    Biol Psychiatry; 1973 Oct; 7(2):129-38. PubMed ID: 4748845
    [No Abstract]   [Full Text] [Related]  

  • 16. N-(3-chloropropyl)phenylethylamine as a possible prodrug of beta-phenylethylamine: studies in the rat brain.
    Rao TS; Baker GB; Coutts RT
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(2-3):301-8. PubMed ID: 3628834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral tissue distribution, brain distribution and metabolism of mescaline- 14 C in monkeys.
    Taska RJ; Schoolar JC
    Arch Int Pharmacodyn Ther; 1973 Mar; 202(1):66-78. PubMed ID: 4632858
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of a low dosage of mescaline and 3,4-dimethoxyphenylethylamine under two levels of aversive stimulation.
    Levis DJ; Caldwell DF
    Biol Psychiatry; 1971; 3(3):251-7. PubMed ID: 5163810
    [No Abstract]   [Full Text] [Related]  

  • 19. Tolerance development to a disruptive effect of beta-phenylethylamine (PEA) on a learned behavior in rats.
    Stoff DM; Moja EA; Jeffery DR; Gillin JC; Wyatt RJ
    Psychopharmacology (Berl); 1979 Nov; 66(2):127-31. PubMed ID: 119255
    [No Abstract]   [Full Text] [Related]  

  • 20. Deuterium substitution enhances the effects of beta-phenylethylamine on spontaneous motor activity in the rat.
    Dourish CT; Greenshaw AJ; Boulton AA
    Pharmacol Biochem Behav; 1983 Sep; 19(3):471-5. PubMed ID: 6634898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.